Leadgene develops cutting-edge technologies and high-quality biological raw materials reagents. Its recent achievements and ...

The interdisciplinary care model reduced hospital admissions by 26% and emergency department visits by 30%, indicating improved outpatient management of CKD. Social determinants, such as physical ...

inRegen has developed a treatment for chronic kidney disease (CKD), now in phase 2 trials ... the tissue under good manufacturing practice (GMP) conditions. The selected autologous, healthy ...

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients ...

Oral Soft Tissue Lesion. Abnormal lip pigmentation was the most frequent lesion seen in CKD subjects, seen 81 out of 90 CKD subjects (90%). Other significant lesions seen include candidiasis ...